Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lyell Immunopharma (LYEL) EBIT: 2020-2025

Historic EBIT for Lyell Immunopharma (LYEL) over the last 6 years, with Sep 2025 value amounting to -$37.3 million.

  • Lyell Immunopharma's EBIT rose 26.24% to -$37.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$342.9 million, marking a year-over-year decrease of 57.94%. This contributed to the annual value of -$358.8 million for FY2024, which is 45.24% down from last year.
  • Lyell Immunopharma's EBIT amounted to -$37.3 million in Q3 2025, which was up 20.97% from -$47.1 million recorded in Q2 2025.
  • Lyell Immunopharma's 5-year EBIT high stood at -$14.8 million for Q4 2022, and its period low was -$201.1 million during Q4 2024.
  • Over the past 3 years, Lyell Immunopharma's median EBIT value was -$57.4 million (recorded in 2025), while the average stood at -$68.0 million.
  • Its EBIT has fluctuated over the past 5 years, first skyrocketed by 68.90% in 2022, then plummeted by 302.52% in 2023.
  • Lyell Immunopharma's EBIT (Quarterly) stood at -$47.5 million in 2021, then soared by 68.90% to -$14.8 million in 2022, then plummeted by 302.52% to -$59.5 million in 2023, then slumped by 238.02% to -$201.1 million in 2024, then grew by 26.24% to -$37.3 million in 2025.
  • Its EBIT stands at -$37.3 million for Q3 2025, versus -$47.1 million for Q2 2025 and -$57.4 million for Q1 2025.